HEB = Abk. für heißer Biotechwert?! - 500 Beiträge pro Seite
eröffnet am 30.09.02 23:27:56 von
neuester Beitrag 04.10.02 16:45:32 von
neuester Beitrag 04.10.02 16:45:32 von
Beiträge: 12
ID: 640.724
ID: 640.724
Aufrufe heute: 0
Gesamt: 856
Gesamt: 856
Aktive User: 0
ISIN: US00901B1052 · WKN: A2PREX · Symbol: AIM
0,4251
USD
-0,04 %
-0,0002 USD
Letzter Kurs 02:04:00 NYSE Arca
Neuigkeiten
06.05.24 · globenewswire  |
29.04.24 · globenewswire |
25.04.24 · globenewswire |
18.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4000 | +49,07 | |
| 4,0500 | +26,96 | |
| 1,7600 | +25,53 | |
| 1,6500 | +22,22 | |
| 23,950 | +21,08 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7100 | -20,11 | |
| 13,610 | -20,92 | |
| 7,5000 | -28,30 | |
| 2,2900 | -28,88 | |
| 0,7494 | -32,49 |
Feedback
Der Analyst Andre Garnet von Taglich Brothers stuft das Kursziel von Hemispherx Biopharma von 13.75 $ auf 25.00 $ hoch (mit einem diskontierten momentanen Wert von 21.08 $).
Was ist daran ungewöhnlich?
Nun, die Aktie schloß heute bei 1.05 $. Das Kursziel signalisiert immerhin einen Zuwachs von schlappen 2000%.
Der Analyst unterstellt, daß das Hauptpräparat "Ampligen" mit einer Wahrscheinlichkeit von über 90% sowohl von der FDA als auch von der europäischen Regulierungsbehörden genehmigt wird. Anwendungen von "Ampligen" sind Chronic Fatigue Syndrome (kam übrigens heute ein Bericht in "Volle Kanne" im ZDF) und HIV/AIDS.
Schaut man sich die Zahlen an, sieht HEB ziemlich schwach auf der Brust aus. Bei ca 6 Mio Cash gibt es eine Cashburn Rate von ca 2Mio/Quartal.
Aber es gibt auch ein Letter of Intent (definitive Absichtserklärung) der königlichen Familie der Vereinigten arabischen Emiraten über ein geplantes "MultiMillionInvestment" bei Hemispherx.
Was ist daran ungewöhnlich?
Nun, die Aktie schloß heute bei 1.05 $. Das Kursziel signalisiert immerhin einen Zuwachs von schlappen 2000%.
Der Analyst unterstellt, daß das Hauptpräparat "Ampligen" mit einer Wahrscheinlichkeit von über 90% sowohl von der FDA als auch von der europäischen Regulierungsbehörden genehmigt wird. Anwendungen von "Ampligen" sind Chronic Fatigue Syndrome (kam übrigens heute ein Bericht in "Volle Kanne" im ZDF) und HIV/AIDS.
Schaut man sich die Zahlen an, sieht HEB ziemlich schwach auf der Brust aus. Bei ca 6 Mio Cash gibt es eine Cashburn Rate von ca 2Mio/Quartal.
Aber es gibt auch ein Letter of Intent (definitive Absichtserklärung) der königlichen Familie der Vereinigten arabischen Emiraten über ein geplantes "MultiMillionInvestment" bei Hemispherx.
Scheint mir eine mittelfristige Wette zu sein; vergleichbar vielleicht mit ein paar Lose bei der SKL
Heutiger Schlußkurs 1.77 $
Hätte sich schon sehr gelohnt seit 1.05 $!
Hätte sich schon sehr gelohnt seit 1.05 $!
was,ist da los?Weiß,jemand News???danke!!
Also es gibt keine neueren Nachrichten als die von meinem 1. Posting!
Gemessen an dem Zielkurs von über 20 $ ist der heutige Schlußkurs von 2.32 $ immer noch ein Schnäppchen.
Who dares wins.
Gemessen an dem Zielkurs von über 20 $ ist der heutige Schlußkurs von 2.32 $ immer noch ein Schnäppchen.
Who dares wins.
Trading Spotlight
also meine meinung dazu:
* eine (einzelne)analystenmeinung macht noch lange keinen börsensommer ... und mal ehrlich leute: was geben wir mit den erfahrungen der letzten zwei jahr noch auf eine analsystenmeinung???
* eine biotchfirma, die so einen heißen umsatzkandidaten in der pipeline hat, braucht sich mit absoluter sicher kein geld bei der arabischen königsfamilie holen (beim besten willen: die haben zwar geld wie sand aber keine ahnung von biotech) frage: warum steigen da keine firmen ein, die AHNUNG haben????
* nach der hype der letzten tage würde ich eh ruhe bewahren, jetzt werden erstmal ganz kräftig gewinne mitgenommen
* eine (einzelne)analystenmeinung macht noch lange keinen börsensommer ... und mal ehrlich leute: was geben wir mit den erfahrungen der letzten zwei jahr noch auf eine analsystenmeinung???
* eine biotchfirma, die so einen heißen umsatzkandidaten in der pipeline hat, braucht sich mit absoluter sicher kein geld bei der arabischen königsfamilie holen (beim besten willen: die haben zwar geld wie sand aber keine ahnung von biotech) frage: warum steigen da keine firmen ein, die AHNUNG haben????
* nach der hype der letzten tage würde ich eh ruhe bewahren, jetzt werden erstmal ganz kräftig gewinne mitgenommen
Ich danke für den Beitrag von "tippse".
Ich habe den Thread aufgemacht, weil ich es ungewöhnlich finde, daß ein Analyst eine Aktie hochstuft, obwohl ja schon das alte Kursziel meilenweit vom Tageskurs entfernt war.
Als Langfristanlage würde ich HEB nicht empfehlen; dazu gibt es viel zu viele Wenn`s.
Wer in den Wert investiert, der weiß, wie man mit einem "heißen" Kandidaten umzugehen hat, also z.B. nur mit striktem Stopp-Loss.
Ich habe den Thread aufgemacht, weil ich es ungewöhnlich finde, daß ein Analyst eine Aktie hochstuft, obwohl ja schon das alte Kursziel meilenweit vom Tageskurs entfernt war.
Als Langfristanlage würde ich HEB nicht empfehlen; dazu gibt es viel zu viele Wenn`s.
Wer in den Wert investiert, der weiß, wie man mit einem "heißen" Kandidaten umzugehen hat, also z.B. nur mit striktem Stopp-Loss.
**************MIT VORSICHT ZU GENIESSEN *****************
Ich hatte sie gestern schon ins BOARD gestellt !!!!!!!!
**************MIT VORSICHT ZU GENIESSEN *****************
The Hemispherx Story
Hemispherx is a 34-year-old alleged drug company that has never filed a New Drug Application ("NDA" with the FDA or completed a Phase III trial, despite claiming potential efficacy based on pre-clinical and Phase II testing in many different diseases including CFS, hepatitis, cancer and HIV. Simultaneously with failing to file an NDA, Hemispherx has used irregular and non-reproducible medical studies, authored by individuals with ties to Hemispherx, to perpetuate the fraudulent promotion of a 30-year-old drug it calls Ampligen. Ampligen is a 1970s substance once studied, along with many other failed dRNAs, as a potential interferon inducer before interferon itself became available as a prescription drug.
Hemispherx was a defunct company before it was brought public in 1995 by Stratton Oakmont, Inc. Hemispherx was one of Stratton’s last fraudulent initial public offerings ("IPO" before Stratton was shut down for fraudulent sales and trading practices. In fact, Stratton’s principals pled guilty in September 1999 to a number of charges, including using HEB’s IPO to defraud the public. Since its fraudulent IPO, Hemispherx paid U.S. and international stock promoters to create investor demand for its AMEX-listed shares. As of June 30, 2000, Hemispherx’s insiders and stock promoters had bought at least 15,721,560 shares directly from Hemispherx at below market prices, which were then sold to the public at inflated prices. After concluding a preliminary investigation, the U.S. Securities and Exchange Commission commenced a formal securities fraud investigation of Hemispherx’s Ampligen-based stock promotion. The investigation is on going.
A recurring part of Hemispherx’s fraud is the unauthorized use of the names and, by extension, the images of various not-for-profit health advocacy organizations in its press releases. In fact, these groups have specifically objected to being mentioned by HEB as part of its stock promotion. On September 21, 1998, Hemispherx issued a release stating that the CFIDS Network, Inc., a CFIDS patients’ organization, supported Ampligen and considered it a safe drug. However, CFIDS Network President Ronald G. Smith wrote a letter to Dr. William A. Carter, Chairman and Chief Executive Officer of Hemispherx denying any CFIDS Network involvement in the release and accusing Hemispherx of slander. The CFIDS Network then issued a press release stating, "…In our experience, no PWC [person with CFIDS] has received lasting benefits from this medication [Ampligen]. Many suffer from a myriad of side effects." Nevertheless, Hemispherx issued a second press release restating their initial press release and knowingly reiterating their false information.
Hemispherx also announced in press releases that it presented HIV test findings at a conference sponsored by Search For A Cure, ("SFAC" an AIDS not-for-profit organization. SFAC sent a letter to Dr. Carter stating that "Hemispherx did not make a presentation at the conference and its many requests to make a presentation were turned down by SFAC." The SFAC letter further states that "your misstatements are a misuse of the SFAC name and appear to imply an endorsement or legitimacy by association with SFAC, which is untrue." The letter served as a demand for a prominent correction and to cease and desist from further misuse of the SFAC name. Again, Hemispherx ignored the letter and issued another press release making the same false claims.
On May 17, 1999, a group calling itself the AIDS Treatment Technical Assistance Council ("ATTAC" issued a press release over the PR Newswire stating that Ampligen was a clinically promising therapy for HIV. David Miller was named as the Executive Director of ATTAC. We found no record of a non-profit group registered or incorporated under the name ATTAC. The ATTAC press release was paid for by Mitchell Abrahams. Mitch Abrahams is disclosed in a 1999 Hemispherx SEC filing as a recipient of 20,000 privately issued shares of Hemispherx stock.
Ampligen has never received FDA marketing approval. In July 2000, in addition to the October 1998 FDA letter, Hemispherx received two "warning letters" from the FDA. The FDA detailed specific press releases and disclosures made by Hemispherx that constituted promotion of Ampligen as safe and effective in violation of FDA regulations. The FDA stated "your promotional materials are false and misleading in that they fail to disclose facts that are material in light of representations made about Ampligen." In particular, Hemispherx failed to disclose risk information associated with the use of Ampligen. The FDA stated "toxicities that have been reported in dose-escalating studies of Ampligen in HIV-infected patients include, but are not limited to, flushing, chills, fever, chest tightness, nausea, malaise, shortness of breath, flu-like symptoms, leukopenia, neutropenia, and leukocytosis." William A. Carter has also been accused of irregularities and fired from medical research positions at Roswell Park Memorial Institute and even from Hemispherx itself.
On September 21, 1998 Hemispherx announced that it had agreed to invest in California Institute of Molecular Medicine, Inc. ("CIMM". CIMM was one-year-old. In 1990, Zaki Salahuddin, one of CIMM’s two founders, was indicted by the United States Attorney’s Baltimore office. He pled guilty to felony charges that included funneling contracts to a company partly owned by his wife while he was on staff at the National Cancer Institute. In announcing the partnership Hemispherx stated that it admired Salahuddin’s outstanding achievements but made no mention of his indictment or guilty plea. On February 17, 2000, Hemispherx refers to positive medical findings at CIMM, now an affiliated company, as an alleged reason to claim Ampligen has potential as a treatment for HIV.
A U.S. House of Representatives Subcommittee investigated Carter and his associates for scientific fraud. Carter also has been charged with personally defrauding $1 million from an AIDS patient who sought admission to an Ampligen AIDS trial, which resoundingly failed and was halted. E.I. Du Pont de Nemours and Company (NYSE: DD), which sponsored the failed AIDS trial charged Carter and his colleagues in a lawsuit with scientific fraud.
Another part of Hemispherx’s fraud is the use of legal proceedings to fight opponents. Hemispherx and Dr. Carter have a history of making irregular medical claims and taking legal action against parties that question their claims. Hemispherx repeatedly have filed lawsuits claiming themselves as victims of a series of conspiracies.
JS200
Ich hatte sie gestern schon ins BOARD gestellt !!!!!!!!
**************MIT VORSICHT ZU GENIESSEN *****************
The Hemispherx Story
Hemispherx is a 34-year-old alleged drug company that has never filed a New Drug Application ("NDA" with the FDA or completed a Phase III trial, despite claiming potential efficacy based on pre-clinical and Phase II testing in many different diseases including CFS, hepatitis, cancer and HIV. Simultaneously with failing to file an NDA, Hemispherx has used irregular and non-reproducible medical studies, authored by individuals with ties to Hemispherx, to perpetuate the fraudulent promotion of a 30-year-old drug it calls Ampligen. Ampligen is a 1970s substance once studied, along with many other failed dRNAs, as a potential interferon inducer before interferon itself became available as a prescription drug.
Hemispherx was a defunct company before it was brought public in 1995 by Stratton Oakmont, Inc. Hemispherx was one of Stratton’s last fraudulent initial public offerings ("IPO" before Stratton was shut down for fraudulent sales and trading practices. In fact, Stratton’s principals pled guilty in September 1999 to a number of charges, including using HEB’s IPO to defraud the public. Since its fraudulent IPO, Hemispherx paid U.S. and international stock promoters to create investor demand for its AMEX-listed shares. As of June 30, 2000, Hemispherx’s insiders and stock promoters had bought at least 15,721,560 shares directly from Hemispherx at below market prices, which were then sold to the public at inflated prices. After concluding a preliminary investigation, the U.S. Securities and Exchange Commission commenced a formal securities fraud investigation of Hemispherx’s Ampligen-based stock promotion. The investigation is on going.
A recurring part of Hemispherx’s fraud is the unauthorized use of the names and, by extension, the images of various not-for-profit health advocacy organizations in its press releases. In fact, these groups have specifically objected to being mentioned by HEB as part of its stock promotion. On September 21, 1998, Hemispherx issued a release stating that the CFIDS Network, Inc., a CFIDS patients’ organization, supported Ampligen and considered it a safe drug. However, CFIDS Network President Ronald G. Smith wrote a letter to Dr. William A. Carter, Chairman and Chief Executive Officer of Hemispherx denying any CFIDS Network involvement in the release and accusing Hemispherx of slander. The CFIDS Network then issued a press release stating, "…In our experience, no PWC [person with CFIDS] has received lasting benefits from this medication [Ampligen]. Many suffer from a myriad of side effects." Nevertheless, Hemispherx issued a second press release restating their initial press release and knowingly reiterating their false information.
Hemispherx also announced in press releases that it presented HIV test findings at a conference sponsored by Search For A Cure, ("SFAC" an AIDS not-for-profit organization. SFAC sent a letter to Dr. Carter stating that "Hemispherx did not make a presentation at the conference and its many requests to make a presentation were turned down by SFAC." The SFAC letter further states that "your misstatements are a misuse of the SFAC name and appear to imply an endorsement or legitimacy by association with SFAC, which is untrue." The letter served as a demand for a prominent correction and to cease and desist from further misuse of the SFAC name. Again, Hemispherx ignored the letter and issued another press release making the same false claims.
On May 17, 1999, a group calling itself the AIDS Treatment Technical Assistance Council ("ATTAC" issued a press release over the PR Newswire stating that Ampligen was a clinically promising therapy for HIV. David Miller was named as the Executive Director of ATTAC. We found no record of a non-profit group registered or incorporated under the name ATTAC. The ATTAC press release was paid for by Mitchell Abrahams. Mitch Abrahams is disclosed in a 1999 Hemispherx SEC filing as a recipient of 20,000 privately issued shares of Hemispherx stock.
Ampligen has never received FDA marketing approval. In July 2000, in addition to the October 1998 FDA letter, Hemispherx received two "warning letters" from the FDA. The FDA detailed specific press releases and disclosures made by Hemispherx that constituted promotion of Ampligen as safe and effective in violation of FDA regulations. The FDA stated "your promotional materials are false and misleading in that they fail to disclose facts that are material in light of representations made about Ampligen." In particular, Hemispherx failed to disclose risk information associated with the use of Ampligen. The FDA stated "toxicities that have been reported in dose-escalating studies of Ampligen in HIV-infected patients include, but are not limited to, flushing, chills, fever, chest tightness, nausea, malaise, shortness of breath, flu-like symptoms, leukopenia, neutropenia, and leukocytosis." William A. Carter has also been accused of irregularities and fired from medical research positions at Roswell Park Memorial Institute and even from Hemispherx itself.
On September 21, 1998 Hemispherx announced that it had agreed to invest in California Institute of Molecular Medicine, Inc. ("CIMM". CIMM was one-year-old. In 1990, Zaki Salahuddin, one of CIMM’s two founders, was indicted by the United States Attorney’s Baltimore office. He pled guilty to felony charges that included funneling contracts to a company partly owned by his wife while he was on staff at the National Cancer Institute. In announcing the partnership Hemispherx stated that it admired Salahuddin’s outstanding achievements but made no mention of his indictment or guilty plea. On February 17, 2000, Hemispherx refers to positive medical findings at CIMM, now an affiliated company, as an alleged reason to claim Ampligen has potential as a treatment for HIV.
A U.S. House of Representatives Subcommittee investigated Carter and his associates for scientific fraud. Carter also has been charged with personally defrauding $1 million from an AIDS patient who sought admission to an Ampligen AIDS trial, which resoundingly failed and was halted. E.I. Du Pont de Nemours and Company (NYSE: DD), which sponsored the failed AIDS trial charged Carter and his colleagues in a lawsuit with scientific fraud.
Another part of Hemispherx’s fraud is the use of legal proceedings to fight opponents. Hemispherx and Dr. Carter have a history of making irregular medical claims and taking legal action against parties that question their claims. Hemispherx repeatedly have filed lawsuits claiming themselves as victims of a series of conspiracies.
JS200
09/30/2002 (09:42 ET) Taglich Brothers Announces Investment Opinion: Taglich Brothers Upgrades Hemispherx BioPharma, Inc. to Buy - Business Wire
09/30/2002 (09:09 ET) Taglich Brothers Updated Research Report On Hemispherx Raises Target Price From $13.75 to $25.00 With a Discounted Present Value of $21.08 - Business Wire
09/27/2002 (12:26 ET) 52W LOW: New 52-Wk Low for HEB @ $0.850 dn13.27% - Knobias ?????????????????????????????
09/24/2002 (10:01 ET) 52W LOW: New 52-Wk Low for HEB @ $0.900 dn13.46% - Knobias ?????????????????????????
09/23/2002 (10:12 ET) 52W LOW: New 52-Wk Low for HEB @ $1.200 dn4% - Knobias ????????????????????????
JS200
09/30/2002 (09:09 ET) Taglich Brothers Updated Research Report On Hemispherx Raises Target Price From $13.75 to $25.00 With a Discounted Present Value of $21.08 - Business Wire
09/27/2002 (12:26 ET) 52W LOW: New 52-Wk Low for HEB @ $0.850 dn13.27% - Knobias ?????????????????????????????
09/24/2002 (10:01 ET) 52W LOW: New 52-Wk Low for HEB @ $0.900 dn13.46% - Knobias ?????????????????????????
09/23/2002 (10:12 ET) 52W LOW: New 52-Wk Low for HEB @ $1.200 dn4% - Knobias ????????????????????????
JS200
@JS:
Da hast Du ja fleissig von Manuel Asensio`s Homepage kopiert. Diese Darstellung ist jedoch in vielen Punkten völlig verfälscht und "biased" - Asensio ist ein bekannter Shortseller und hatte zumindest früher eine große Shortposition in HEB. Zudem sind die Methoden, mit denen er seine Shortkandidaten niedermacht - diplomatisch ausgedrückt! - sehr umstritten. Man könnte ihn, wenn man so wollte, auch als niederträchtiges A......h titulieren. Wer versuchen will, sich ein objektives Bild über HEB zu machen, sollte unter messages.yahoo.com "HEB" suchen und das Board durchackern. Dort gibt es freilich auch bezahlte Basher (wie z.B. "marin655" ). Früher gut, jetzt aber etwas am absterben, ist das HEB-Board unter www.fool.com, da nur bezahlenden Mitgliedern zugänglich.
Also, JS, ich hoffe, daß Dir das nicht klar war - auf Bashertypen können wir hier nämlich gut verzichten.
Gruß, Götz
Da hast Du ja fleissig von Manuel Asensio`s Homepage kopiert. Diese Darstellung ist jedoch in vielen Punkten völlig verfälscht und "biased" - Asensio ist ein bekannter Shortseller und hatte zumindest früher eine große Shortposition in HEB. Zudem sind die Methoden, mit denen er seine Shortkandidaten niedermacht - diplomatisch ausgedrückt! - sehr umstritten. Man könnte ihn, wenn man so wollte, auch als niederträchtiges A......h titulieren. Wer versuchen will, sich ein objektives Bild über HEB zu machen, sollte unter messages.yahoo.com "HEB" suchen und das Board durchackern. Dort gibt es freilich auch bezahlte Basher (wie z.B. "marin655" ). Früher gut, jetzt aber etwas am absterben, ist das HEB-Board unter www.fool.com, da nur bezahlenden Mitgliedern zugänglich.
Also, JS, ich hoffe, daß Dir das nicht klar war - auf Bashertypen können wir hier nämlich gut verzichten.
Gruß, Götz
@tippse:
Es ist keineswegs nur so, daß die arabischen Royals bei HEB einsteigen (die wissen im Übrigen sehr gut, wie man mit Geld umgeht!). Schau Dich unter www.hemispherx.net mal um.
z.B.:
"Philadelphia, PA, Wednesday, June 05, 2002: Hemispherx Biopharma, Inc. (AMEX: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today that its wholly owned subsidiary, Hemispherx Biopharma Europe S.A., has completed an agreement with a wholly owned subsidiary of Laboratorios Del Dr. Esteve S.A., Barcelona Spain.
The agreement includes the investment by Esteve of a substantial amount of convertible securities in Hemispherx Europe on the basis of an evaluation of the Hemispherx Biopharma, Inc. subsidiary of approximately 100 Million Euros. The initial payment, in excess of 1 million Euros, has been received. Further benchmark payments are provided for in the agreement. The relationship between both companies will enable them to collaborate in certain areas in regards to exclusive sale and distribution as well as initiation and conducting of specific clinical trials.
Dr. William Carter, Chairman and CEO of Hemispherx Biopharma Inc, stated "with Esteve`s extensive clinical trial, marketing and distribution expertise, we are extremely excited about successfully establishing this relationship, and we look forward to a long a prosperous future between our companies."
Hemispherx Biopharma, Inc.
Hemispherx Biopharma, Inc., Philadelphia, PA, is a biopharmaceutical company that focuses on the innovative development of ribonucleic acid (RNA) drug technologies intended to enhance the natural anti-viral defense system of the human body, representing a potential new class of pharmaceutical products. Its primary product, Ampligen, is in two phase IIb clinical trials for HIV/AIDS, one Salvage Therapy and one Strategic Treatment Intervention (STI), and a phase III clinical trial for Chronic Fatigue Syndrome (CFS). For more information, please visit the Company`s website at http://www.hemispherx.net. The Company`s experimental programs have not been deemed "safe and effective" by regulatory agencies and thus are presently available only through approved clinical trails being conducted at certain geographic locations with approved physicians.
Laboratorios Del Dr. Esteve S.A.
Laboratorios Del Dr. Esteve S.A., Barcelona, Spain is one of the largest privately owned pharmaceutical companies in Southern Europe. With a turnover of 561 million Euros in 2001, distribution of its products to over 80 markets worldwide, patents granted in more then 40 countries and with over 2000 employees, Esteve has been able to establish itself as one of the premier pharmaceutical companies in Europe. "
Zitat Ende.
Gruß,
Götz
Es ist keineswegs nur so, daß die arabischen Royals bei HEB einsteigen (die wissen im Übrigen sehr gut, wie man mit Geld umgeht!). Schau Dich unter www.hemispherx.net mal um.
z.B.:
"Philadelphia, PA, Wednesday, June 05, 2002: Hemispherx Biopharma, Inc. (AMEX: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today that its wholly owned subsidiary, Hemispherx Biopharma Europe S.A., has completed an agreement with a wholly owned subsidiary of Laboratorios Del Dr. Esteve S.A., Barcelona Spain.
The agreement includes the investment by Esteve of a substantial amount of convertible securities in Hemispherx Europe on the basis of an evaluation of the Hemispherx Biopharma, Inc. subsidiary of approximately 100 Million Euros. The initial payment, in excess of 1 million Euros, has been received. Further benchmark payments are provided for in the agreement. The relationship between both companies will enable them to collaborate in certain areas in regards to exclusive sale and distribution as well as initiation and conducting of specific clinical trials.
Dr. William Carter, Chairman and CEO of Hemispherx Biopharma Inc, stated "with Esteve`s extensive clinical trial, marketing and distribution expertise, we are extremely excited about successfully establishing this relationship, and we look forward to a long a prosperous future between our companies."
Hemispherx Biopharma, Inc.
Hemispherx Biopharma, Inc., Philadelphia, PA, is a biopharmaceutical company that focuses on the innovative development of ribonucleic acid (RNA) drug technologies intended to enhance the natural anti-viral defense system of the human body, representing a potential new class of pharmaceutical products. Its primary product, Ampligen, is in two phase IIb clinical trials for HIV/AIDS, one Salvage Therapy and one Strategic Treatment Intervention (STI), and a phase III clinical trial for Chronic Fatigue Syndrome (CFS). For more information, please visit the Company`s website at http://www.hemispherx.net. The Company`s experimental programs have not been deemed "safe and effective" by regulatory agencies and thus are presently available only through approved clinical trails being conducted at certain geographic locations with approved physicians.
Laboratorios Del Dr. Esteve S.A.
Laboratorios Del Dr. Esteve S.A., Barcelona, Spain is one of the largest privately owned pharmaceutical companies in Southern Europe. With a turnover of 561 million Euros in 2001, distribution of its products to over 80 markets worldwide, patents granted in more then 40 countries and with over 2000 employees, Esteve has been able to establish itself as one of the premier pharmaceutical companies in Europe. "
Zitat Ende.
Gruß,
Götz
@GÖTZ
Es war nicht mein Ziel zu Bashen, oder zu mindest nicht gewollt.
Ich habe gestern einen Tread über Heb aufgemacht und habe von @ALFINANZ diese Infos bekommen. Sollte rein als INFO gelten.
Gruss
JS200
Es war nicht mein Ziel zu Bashen, oder zu mindest nicht gewollt.
Ich habe gestern einen Tread über Heb aufgemacht und habe von @ALFINANZ diese Infos bekommen. Sollte rein als INFO gelten.
Gruss
JS200
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -1,58 | |
| +0,42 | |
| -1,37 | |
| -1,55 | |
| -0,12 | |
| -0,07 | |
| +2,09 | |
| +0,12 | |
| 0,00 | |
| -3,04 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 294 | ||
| 108 | ||
| 108 | ||
| 77 | ||
| 70 | ||
| 64 | ||
| 60 | ||
| 48 | ||
| 45 | ||
| 44 |
| Zeit | Titel |
|---|---|
| 15.04.24 |